KR20190140962A - 오피오이드 수용체(mor) 작용제 염, 이의 푸마레이트 염 i 결정 형태 및 이의 제조 방법 - Google Patents

오피오이드 수용체(mor) 작용제 염, 이의 푸마레이트 염 i 결정 형태 및 이의 제조 방법 Download PDF

Info

Publication number
KR20190140962A
KR20190140962A KR1020197033496A KR20197033496A KR20190140962A KR 20190140962 A KR20190140962 A KR 20190140962A KR 1020197033496 A KR1020197033496 A KR 1020197033496A KR 20197033496 A KR20197033496 A KR 20197033496A KR 20190140962 A KR20190140962 A KR 20190140962A
Authority
KR
South Korea
Prior art keywords
solvent
formula
crystal form
compound
ether
Prior art date
Application number
KR1020197033496A
Other languages
English (en)
Korean (ko)
Inventor
린 왕
리쿤 왕
Original Assignee
지앙수 헨그루이 메디슨 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지앙수 헨그루이 메디슨 컴퍼니 리미티드 filed Critical 지앙수 헨그루이 메디슨 컴퍼니 리미티드
Publication of KR20190140962A publication Critical patent/KR20190140962A/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
KR1020197033496A 2017-04-14 2018-04-13 오피오이드 수용체(mor) 작용제 염, 이의 푸마레이트 염 i 결정 형태 및 이의 제조 방법 KR20190140962A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710242119.3 2017-04-14
CN201710242119 2017-04-14
PCT/CN2018/082935 WO2018188643A1 (zh) 2017-04-14 2018-04-13 一种阿片样物质受体(mor)激动剂的盐、其富马酸盐i晶型及制备方法

Publications (1)

Publication Number Publication Date
KR20190140962A true KR20190140962A (ko) 2019-12-20

Family

ID=63792318

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197033496A KR20190140962A (ko) 2017-04-14 2018-04-13 오피오이드 수용체(mor) 작용제 염, 이의 푸마레이트 염 i 결정 형태 및 이의 제조 방법

Country Status (23)

Country Link
US (2) US11014914B2 (pt)
EP (1) EP3610875B1 (pt)
JP (1) JP7153030B6 (pt)
KR (1) KR20190140962A (pt)
CN (1) CN110049980B (pt)
AU (1) AU2018251119B2 (pt)
BR (1) BR112019021447A2 (pt)
CA (1) CA3057383A1 (pt)
CY (1) CY1124063T1 (pt)
DK (1) DK3610875T3 (pt)
ES (1) ES2828636T3 (pt)
HR (1) HRP20210022T1 (pt)
HU (1) HUE053244T2 (pt)
LT (1) LT3610875T (pt)
MX (1) MX2019012251A (pt)
MY (1) MY196571A (pt)
PL (1) PL3610875T3 (pt)
PT (1) PT3610875T (pt)
RS (1) RS61193B1 (pt)
SI (1) SI3610875T1 (pt)
TW (1) TWI682929B (pt)
UA (1) UA124400C2 (pt)
WO (1) WO2018188643A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018188641A1 (zh) * 2017-04-14 2018-10-18 江苏恒瑞医药股份有限公司 一种mor激动剂与kor激动剂的药物组合物及其用途
RS61193B1 (sr) * 2017-04-14 2021-01-29 Jiangsu hengrui medicine co ltd So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje
WO2019205983A1 (zh) * 2018-04-28 2019-10-31 四川科伦博泰生物医药股份有限公司 氧杂螺环类化合物及其制备方法和用途
CN112638906B (zh) * 2018-10-12 2022-05-27 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN112638907B (zh) * 2018-10-12 2022-04-12 江苏恒瑞医药股份有限公司 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法
CN111662284B (zh) * 2019-03-06 2021-08-10 上海海雁医药科技有限公司 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途
KR20210113824A (ko) 2020-03-09 2021-09-17 건국대학교 산학협력단 뮤 오피오이드 수용체의 활성화제를 유효성분으로 포함하는 기분 장애의 예방용 조성물
EP4361154A1 (en) * 2021-07-13 2024-05-01 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pharmaceutically acceptable salt of mor receptor agonist, and polymorph thereof and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA025456B1 (ru) 2011-03-23 2016-12-30 Тревена, Инк. Лиганды опиоидных рецепторов и способы их применения и получения
EP3354649B1 (en) 2015-10-15 2019-12-04 Jiangsu Hengrui Medicine Co., Ltd. Oxa spiro derivative, preparation method therefor, and applications thereof in medicines
RS61193B1 (sr) * 2017-04-14 2021-01-29 Jiangsu hengrui medicine co ltd So agonista opijatnog receptora (mor), kristalni oblik i fumaratne soli iste i postupak za njihovo dobijanje

Also Published As

Publication number Publication date
CA3057383A1 (en) 2018-10-18
AU2018251119A1 (en) 2019-11-07
DK3610875T3 (da) 2020-12-21
AU2018251119B2 (en) 2021-07-29
US11014914B2 (en) 2021-05-25
LT3610875T (lt) 2020-11-25
CN110049980A (zh) 2019-07-23
ES2828636T3 (es) 2021-05-27
PL3610875T3 (pl) 2021-04-19
US20200048229A1 (en) 2020-02-13
RU2019136088A3 (pt) 2021-06-16
WO2018188643A1 (zh) 2018-10-18
HRP20210022T1 (hr) 2021-03-05
TWI682929B (zh) 2020-01-21
TW201837033A (zh) 2018-10-16
CN110049980B (zh) 2020-10-20
MX2019012251A (es) 2019-11-28
RU2019136088A (ru) 2021-05-14
JP2020516642A (ja) 2020-06-11
EP3610875A1 (en) 2020-02-19
PT3610875T (pt) 2020-11-25
MY196571A (en) 2023-04-19
RS61193B1 (sr) 2021-01-29
JP7153030B6 (ja) 2023-07-24
CY1124063T1 (el) 2022-03-24
EP3610875A4 (en) 2020-02-19
SI3610875T1 (sl) 2021-02-26
UA124400C2 (uk) 2021-09-08
JP7153030B2 (ja) 2022-10-13
BR112019021447A2 (pt) 2020-05-05
EP3610875B1 (en) 2020-10-07
US20210130332A1 (en) 2021-05-06
HUE053244T2 (hu) 2021-06-28

Similar Documents

Publication Publication Date Title
KR20190140962A (ko) 오피오이드 수용체(mor) 작용제 염, 이의 푸마레이트 염 i 결정 형태 및 이의 제조 방법
CN108727347B (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
CN103476770A (zh) 新的阿法替尼盐和多晶型物
JP2022024034A (ja) ピロリジン化合物の結晶
WO2016140501A1 (en) Pyridine n-oxide for enhancer of zeste homolog 2 inhibitors
CN109937200B (zh) 一种苯并呋喃类衍生物游离碱的晶型及制备方法
TWI774704B (zh) 一種ＧｎＲＨ受體拮抗劑的結晶形式及其製備方法
TW201827436A (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的晶型及其製備方法
TWI745764B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
RU2779119C2 (ru) Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения
WO2017041622A1 (zh) 一种雄性激素受体抑制剂的结晶形式及其制备方法
TWI717859B (zh) 一種鴉片類物質受體激動劑的結晶形式及製備方法
TWI810344B (zh) 氮雜環丁烷衍生物的硼酸酯
CN112442106A (zh) 一种多肽化合物的固体形式和在医药上的应用
JP6985137B2 (ja) スルホンアミド化合物の結晶形
AU2021337109A9 (en) Phenol derivative

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right